Veracyte, Inc. (NASDAQ:VCYT) Holdings Lowered by Quent Capital LLC

Quent Capital LLC trimmed its stake in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 49.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,354 shares of the biotechnology company's stock after selling 11,118 shares during the period. Quent Capital LLC's holdings in Veracyte were worth $337,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Jones Financial Companies Lllp lifted its position in shares of Veracyte by 49.7% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the biotechnology company's stock worth $28,000 after buying an additional 237 shares in the last quarter. Versant Capital Management Inc boosted its holdings in shares of Veracyte by 1,267.6% in the 1st quarter. Versant Capital Management Inc now owns 930 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 862 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in Veracyte in the 4th quarter worth approximately $64,000. US Bancorp DE grew its stake in shares of Veracyte by 57.4% during the fourth quarter. US Bancorp DE now owns 1,774 shares of the biotechnology company's stock valued at $70,000 after buying an additional 647 shares during the last quarter. Finally, Principal Securities Inc. grew its stake in shares of Veracyte by 34.1% during the fourth quarter. Principal Securities Inc. now owns 1,909 shares of the biotechnology company's stock valued at $76,000 after buying an additional 485 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have commented on VCYT shares. UBS Group lowered their price objective on shares of Veracyte from $49.00 to $42.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Stephens reaffirmed an "overweight" rating and set a $45.00 target price on shares of Veracyte in a research note on Wednesday, March 26th. Needham & Company LLC lowered their price target on shares of Veracyte from $51.00 to $41.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Guggenheim decreased their price objective on shares of Veracyte from $45.00 to $37.00 and set a "buy" rating for the company in a research note on Wednesday, April 9th. Finally, Wall Street Zen lowered shares of Veracyte from a "buy" rating to a "hold" rating in a report on Friday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $40.90.

Veracyte Trading Down 0.9%

NASDAQ:VCYT traded down $0.24 during mid-day trading on Tuesday, hitting $26.50. The stock had a trading volume of 829,664 shares, compared to its average volume of 900,330. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -176.67 and a beta of 2.14. The company has a 50 day simple moving average of $29.87 and a 200-day simple moving average of $36.26. Veracyte, Inc. has a 52 week low of $19.73 and a 52 week high of $47.32.

Veracyte Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.